
Anti-Parkinsonian Activity of Ganoderma Lucidum in Experimentally Induced Parkinson’s Disease
Author(s) -
Sana Aslam,
Muhammad Aslam,
Hania Kauser,
Sara Naqvi
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i52b33626
Subject(s) - rotenone , superoxide dismutase , malondialdehyde , pharmacology , lipid peroxidation , parkinson's disease , chemistry , neuroprotection , catalase , antioxidant , biochemistry , biology , medicine , mitochondrion , disease
Background: Parkinson's illness has been proclaimed as the second most neurodegenerative problem on the planet. Ganoderma lucidum is considered as a genuine restorative mushroom.
Aim: Our study was directed to assess the antiparkinsonian action of Ganoderma lucidum in rotenone-incited Parkinson’s disease in male Wistar rodents.
Methods: The impacts of Ganoderma lucidum were concentrated on catalepsy, muscle rigidity.
Results: Ganoderma lucidum fundamentally decreased the expanded length of catalepsy. Rotenone essentially initiated the disturbance of motor neurons as demonstrated by muscle rigidity of muscles and decreased locomotion. Ganoderma lucidum alleviated the disturbance of motor neurons by rotarod execution and locomotor action of the creatures. The exercises of cell reinforcement proteins catalase and superoxide dismutase, and the level of tripeptide glutathione were essentially diminished by rotenone. Besides, rotenone extended the level of lipid peroxidation thing malondialdehyde. Notwithstanding, Ganoderma lucidum supplementation to rotenone-infused rats essentially extended the degrees of superoxide dismutase, catalase, and glutathione, and diminished the level of malondialdehyde
Conclusion: Our study firmly supports the notion that Ganoderma lucidum has neuroprotective and antiparkinsonian action.